Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology

A Busca; C Cattaneo; E De Carolis; G Nadali; M Offidani; M Picardi; A Candoni; E Ceresoli; M Criscuolo; M Delia; R Della Pepa; I Del Principe; RR Fanci; F Farina; N Fracchiolla; C Giordano; M Malagola; F Marchesi; M Piedimonte; L Prezioso; AM Quinto; A Spolzino; MC Tisi; F Trastulli; EM Trecarichi; P Zappasodi; M Tumbarello; L Pagano; on behalf of SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

doi:10.1016/j.critrevonc.2020.103203

Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology

A Busca, C Cattaneo, E De Carolis, G Nadali, M Offidani, M Picardi, A Candoni, E Ceresoli, M Criscuolo, M Delia, R Della Pepa, I Del Principe, RR Fanci, F Farina, N Fracchiolla, C Giordano, M Malagola, F Marchesi, M Piedimonte, L PreziosoAM Quinto, A Spolzino, MC Tisi, F Trastulli, EM Trecarichi, P Zappasodi, M Tumbarello, L Pagano, on behalf of SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

Research output: Contribution to journal › Article › peer-review

Abstract

The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections. © 2020

Original language	English
Article number	103203
Journal	Crit. Rev. Oncol. Hematol.
Volume	158
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103203
Publication status	Published - 2021

Access to Document

10.1016/j.critrevonc.2020.103203

Cite this

Busca, A., Cattaneo, C., De Carolis, E., Nadali, G., Offidani, M., Picardi, M., Candoni, A., Ceresoli, E., Criscuolo, M., Delia, M., Della Pepa, R., Del Principe, I., Fanci, RR., Farina, F., Fracchiolla, N., Giordano, C., Malagola, M., Marchesi, F., Piedimonte, M., ... EMopatie), O. B. O. SEIFEM. (2021). Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology. Crit. Rev. Oncol. Hematol., 158, [103203]. https://doi.org/10.1016/j.critrevonc.2020.103203

Busca, A, Cattaneo, C, De Carolis, E, Nadali, G, Offidani, M, Picardi, M, Candoni, A, Ceresoli, E, Criscuolo, M, Delia, M, Della Pepa, R, Del Principe, I, Fanci, RR, Farina, F , Fracchiolla, N, Giordano, C, Malagola, M, Marchesi, F, Piedimonte, M, Prezioso, L, Quinto, AM, Spolzino, A, Tisi, MC, Trastulli, F, Trecarichi, EM, Zappasodi, P , Tumbarello, M , Pagano, L & EMopatie), OBOSEIFEM 2021, 'Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology', Crit. Rev. Oncol. Hematol., vol. 158, 103203. https://doi.org/10.1016/j.critrevonc.2020.103203

@article{8840f4555d4542e78c6cad4475eee1ec,

title = "Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology",

abstract = "The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections. {\textcopyright} 2020",

author = "A Busca and C Cattaneo and {De Carolis}, E and G Nadali and M Offidani and M Picardi and A Candoni and E Ceresoli and M Criscuolo and M Delia and {Della Pepa}, R and {Del Principe}, I and RR Fanci and F Farina and N Fracchiolla and C Giordano and M Malagola and F Marchesi and M Piedimonte and L Prezioso and AM Quinto and A Spolzino and MC Tisi and F Trastulli and EM Trecarichi and P Zappasodi and M Tumbarello and L Pagano and EMopatie), {on behalf of SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle}",

year = "2021",

doi = "10.1016/j.critrevonc.2020.103203",

language = "English",

volume = "158",

journal = "Crit. Rev. Oncol. Hematol.",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

T2 - Critical Reviews in Oncology/Hematology

AU - Busca, A

AU - Cattaneo, C

AU - De Carolis, E

AU - Nadali, G

AU - Offidani, M

AU - Picardi, M

AU - Candoni, A

AU - Ceresoli, E

AU - Criscuolo, M

AU - Delia, M

AU - Della Pepa, R

AU - Del Principe, I

AU - Fanci, RR

AU - Farina, F

AU - Fracchiolla, N

AU - Giordano, C

AU - Malagola, M

AU - Marchesi, F

AU - Piedimonte, M

AU - Prezioso, L

AU - Quinto, AM

AU - Spolzino, A

AU - Tisi, MC

AU - Trastulli, F

AU - Trecarichi, EM

AU - Zappasodi, P

AU - Tumbarello, M

AU - Pagano, L

AU - EMopatie), on behalf of SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle

PY - 2021

Y1 - 2021

N2 - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections. © 2020

AB - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections. © 2020

U2 - 10.1016/j.critrevonc.2020.103203

DO - 10.1016/j.critrevonc.2020.103203

M3 - Article

SN - 1040-8428

VL - 158

JO - Crit. Rev. Oncol. Hematol.

JF - Crit. Rev. Oncol. Hematol.

M1 - 103203

ER -

Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper: Critical Reviews in Oncology/Hematology

Abstract

Access to Document

Fingerprint

Cite this